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Background-—The ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic
Hypertension) trial demonstrated that combination therapy using amlodipine, rather than hydrochlorothiazide, in conjunction with
benazepril provided greater cardiovascular risk reduction among high-risk hypertensive patients. Few trials have evaluated the
effect of prior antihypertensive therapy used among participants on the study outcomes.
Methods and Results-—In a post hoc observational analysis, we examined the characteristics of the drug regimens taken before
trial enrollment in the context of the primary composite outcome (death from cardiovascular causes, nonfatal myocardial
infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac death, and coronary revascularization). In
the “primary subgroup” (n=4475), patients previously taking any renin-angiotensin system blockade plus either a diuretic or a
calcium channel blocker alone or as part of their antihypertensive regimen, there were 206 of 2193 (9.4%) versus 281 of 2282
(12.3%) primary composite events among those randomized to combination therapy involving amlodipine versus hydrochloroth-
iazide, respectively (adjusted Cox proportional hazard ratio, 0.74; 95% confidence interval, 0.62–0.89; P=0.0015). All other
participants (n=6975) previously taking any antihypertensive regimen not included in the primary subgroup also benefited from
randomization to amlodipine plus benazepril (adjusted hazard ratio, 0.84; 95% confidence interval, 0.72–0.98; P=0.024). Outcomes
among most other subgroups, including patients previously taking lipid-lowering medications or dichotomized by prior blood
pressure control status, showed similar results.
Conclusions-—When combined with an angiotensin-converting enzyme inhibitor, amlodipine provides cardiovascular risk reduction
superior to hydrochlorothiazide, largely regardless of prior medication use. These findings add further support for the initial use of
this combination regimen among high-risk hypertensive patients. ( J Am Heart Assoc. 2018;7:e006940. DOI: 10.1161/JAHA.
117.006940.)
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A ntihypertensive therapy is well established to reduce theadverse cardiovascular consequences of high blood
pressure (BP).1 The overall evidence supports that the degree
of BP lowering is the major determinant of the health
benefits.1 Guidelines, therefore, emphasize the importance of
controlling BP as the preeminent goal.2,3 In this regard, it is
important to acknowledge that most hypertensive patients
(eg, 75%) require ≥2 antihypertensive medications to achieve
BP targets.4 As such, the most germane issue to explore in
guiding present-day clinical practice is which combination of
medications (rather than what single agent) provides optimal
cardiovascular protection.5 Although most patients in clinical
trials were taking >1 antihypertensive medication,1 only the
ACCOMPLISH (Avoiding Cardiovascular Events Through Com-
bination Therapy in Patients Living with Systolic Hypertension)
trial was designed to investigate the comparative cardiovas-
cular risk reductions derived from 2 prespecified combination
regimens prescribed as initial therapy.6 The study was
terminated early (mean follow-up, 36 months) because of
the superiority of benazepril+amlodipine compared with
benazepril+hydrochlorothiazide for preventing the primary
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composite outcome (hazard ratio [HR], 0.80; 95% confidence
interval [CI], 0.72–0.90; P<0.001). Subsequent analyses
showed that this benefit occurred among patients with
coronary artery disease7 and diabetes mellitus,8 was superior
for preventing adverse renal outcomes,9 and was not likely a
consequence of subtle BP differences between groups
(ambulatory BP monitoring).10
As with most contemporary trials,1 most patients (97.1%)
entering into the ACCOMPLISH trial had already been
receiving antihypertensive therapy.6 Hence, the main conclu-
sion of the study can most accurately be stated as follows:
switching treated hypertensive individuals to initial combina-
tion therapy composed of benazepril+amlodipine rather than
benazepril+hydrochlorothiazide is more effective for prevent-
ing cardiovascular events. Because of this high rate of
background therapies, it is important to evaluate if the
characteristics of the prior regimens had a modifying effect on
study outcomes. For example, some medication(s) may have
differed in reducing baseline cardiovascular risk (eg, superior
24-hour BP control and fewer adverse metabolic actions) and
could have, thereby, plausibly affected the capacity for the
ensuing randomized treatments to differentially provide
cardiovascular protection. The principal aim of this post hoc
observational analysis was to determine if combination
therapy using benazepril+amlodipine conveys a significant
risk reduction on the primary composite end point in a
subgroup of patients who had already been taking a drug
regimen similar to either of the treatment limbs allocated in
the trial (“primary subgroup”): renin-angiotensin system (RAS)
blockade plus either a thiazide-type diuretic or any calcium
channel blocker (CCB) alone or as part of their antihyperten-
sive regimen. This is a clinically relevant question because
both combination therapy regimens remain recommended
approaches by guidelines2,3 and are considered rational
pharmacological strategies4 commonly used in present-day
practice. In secondary analyses, we explored if prior use of
other antihypertensive regimens, background lipid-lowering
therapy, or previous BP control status may have modified the
benefits derived from allocation to benazepril+amlodipine.
Methods
The overall design and methods of the ACCOMPLISH trial have
been previously described.6 The institutional review boards or
ethics committees of each participating site approved the
protocol, as described in the primary article.6 The data, analytic
methods, and study materials will not be made available to
other researchers for purposes of reproducing the results or
replicating the procedure. In brief, the ACCOMPLISH trial was
an international (5 countries), multicenter (n=548), double-
blind, randomized, clinical outcome trial of 11 056 patients
with hypertension at high risk for cardiovascular disease. The
primary outcome was time to first composite event (death from
cardiovascular causes, nonfatal myocardial infarction, nonfatal
stroke, hospitalization for angina, resuscitation after sudden
cardiac death, and coronary revascularization) compared
between treatment limbs (benazepril+amlodipine versus
benazepril+hydrochlorothiazide). In this post hoc observational
analysis, we aimed to evaluate the effect of prior medication
regimens on the primary study outcome. Before undertaking
the analyses, we a priori defined the primary subgroup as
patients previously taking a regimen similar to either random-
ized treatment subsequently allocated in the trial. This included
individuals taking an RAS blocker (any angiotensin-converting
enzyme inhibitor [ACEI] or angiotensin receptor blocker) plus
either a thiazide-like diuretic or CCB. The 2 antihypertensive
medications could be taken alone (ie, no additional BP
medications) or as part of a larger regimen (≥3 drugs in total),
including any supplementary BP-lowering medications (eg, b or
a blockers). We began the series of analyses with and
highlighted the presentation of our findings in this primary
subgroup because we believed the results from these patients
would yield the overall most clinically relevant information.
These findings specifically inform healthcare providers the sum
benefits together of maintaining an RAS blocker/CCB regimen
if already taking it and switching to this regimen among patients
taking an RAS blocker/diuretic regimen. Subsequent analyses
further evaluated the individual benefits in each of these
subgroups alone, along with several other groups with a viable
sample size.
Clinical Perspective
What Is New?
• When combined with an angiotensin-converting enzyme
inhibitor, amlodipine provided superior cardiovascular risk
protection compared with hydrochlorothiazide, irrespective
of what blood pressure–lowering agents were used in the
past.
What Are the Clinical Implications?
• Because most hypertensive patients (≥75%) require ≥2
medications to achieve blood pressure goals, our observa-
tions support that most patients should consider treatment
with a renin-angiotensin system blocker combined with a
calcium channel blocker as first-line therapy or as part of
the overall therapeutic regimen (if additional drugs are still
required), even if other antihypertensive agent(s) were used
in the past.
• A streamlined strategy of starting initial combination
therapy using a renin-angiotensin system blocker combined
with a calcium channel blocker should be tested versus
current hypertension guidelines in a clinical outcome trial
for the prevention of cardiovascular events.
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Statistical Analyses
The HRs and corresponding 95% CIs related to allocation to
benazepril+amlodipine versus benazepril+hydrochlorothiazide
were assessed among individual subgroups of participants
previously treated with various antihypertensive and other
medication regimens on entering the trial using survival
analyses with Cox proportional hazard models. Specifically,
the Cox models comparing the effectiveness of randomized
treatments were separately evaluated in each of the specified
subgroups of participants. The HRs in the Cox models were
adjusted for baseline age, smoking status, history of myocar-
dial infarction, coronary revascularization, hospitalization for
unstable angina, baseline systolic and diastolic BP levels, and
left ventricular hypertrophy by ECG (covariables related to the
primary end point). All other subgroups evaluated were
analyzed as secondary end points by adjusted Cox propor-
tional hazard models and confined to groups >700 patients
because smaller sample sizes could yield unstable or
unreliable results. Kaplan-Meier estimates with the log-rank
test were also used to estimate and compare the end points
throughout the trial for the 2 treatment groups. In addition to
performing individual subgroup analyses, we also tested for
effect modification on the HRs (by prior treatment subgroup
identifier) in the entire cohort of patients. This was done by
adding an interaction term of the subgroup indicator and
treatment indicator in the Cox model that included all study
participants.
Results
The characteristics of the overall ACCOMPLISH trial cohort
(n=11 506) have been previously described.6 Table 1 pre-
sents the results separated into 2 subgroups: the primary
Table 1. Characteristics of the Participants in the Main
Subgroups (Total N=11 450)
Subject Characteristics
Primary
Subgroup
All Other
Participants P Value
Subjects, n (%) 4475 (39.1) 6975 (60.9) . . .
Sex, n (%) <0.0001
Male 2686 (60.0) 4256 (61.0)
Female 1789 (40.0) 2719 (39.0)
Age, meanSD, y 68.26.9 68.46.9 0.102
≥65 y, n (%) 2948 (65.9) 4652 (66.7) 0.366
≥70 y, n (%) 1812 (40.5) 2864 (41.1) 0.545
Race or ethnic group, n (%) 0.081
Black 615 (13.7) 757 (10.9) <0.0001
White 3682 (82.3) 5919 (84.9) 0.0003
Hispanic 237 (5.3) 385 (5.5) 0.607
Other 164 (3.7) 264 (3.8) 0.741
Region, n (%) <0.0001
United States 3288 (73.5) 4809 (69.0)
Nordic countries 1187 (26.5) 2166 (31.0)
Anthropometrics, meanSD
Weight, kg 89.818.9 87.819.0 <0.0001
Waist circumference, cm 104.715.3 103.315.3 <0.0001
Body mass index, kg/m2 31.46.2 30.66.2 <0.0001
Medications, n (%)
Lipid-lowering agents 3933 (68.4) 4662 (67.6) 0.359
b Blockers 1930 (43.5) 3451 (50.1) <0.0001
Antiplatelet agents 2794 (63.0) 4374 (63.5) 0.641
Hemodynamics, meanSD
Systolic BP, mm Hg 144.818.1 145.818.4 0.007
Diastolic BP, mm Hg 79.310.7 80.510.7 <0.0001
Heart rate, beats/min 70.710.9 70.211.0 0.026
Laboratory values, meanSD
Creatinine, mg/dL 1.00.28 0.980.26 0.0006
Glucose, mg/dL 128.645.5 126.646.9 0.033
Potassium, mmol/dL 4.20.4 4.30.4 <0.0001
Total cholesterol, mg/dL 183.438.9 185.140.1 0.046
HDL-C, mg/dL 49.313.9 49.514.1 0.401
Risk factors, n (%)
Myocardial infarction 948 (21.2) 1755 (25.2) <0.0001
Stroke 565 (12.6) 928 (13.3) 0.293
Hospitalization for
United States
475 (10.6) 848 (12.2) 0.012
Diabetes mellitus 2897 (64.7) 4007 (57.5) <0.0001
Renal disease 319 (7.1) 383 (5.5) 0.0004
Continued
Table 1. Continued
Subject Characteristics
Primary
Subgroup
All Other
Participants P Value
Coronary revascularization,
n (%)
1495 (33.4) 2612 (37.5) <0.0001
CABG 869 (19.4) 1570 (22.5) <0.0001
PCI 814 (18.2) 1359 (19.5) 0.085
Other, n (%)
LVH 573 (13.1) 954 (14.0) 0.172
Current smoking 492 (11.0) 803 (11.5) 0.393
Dyslipidemia 3373 (75.4) 5160 (74.0) 0.094
Atrial fibrillation 297 (6.6) 479 (6.0) 0.632
BP indicates blood pressure; CABG, coronary artery bypass grafting; HDL-C, high-density
lipoprotein cholesterol; LVH, left ventricular hypertrophy; and PCI, percutaneous
coronary intervention.
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subgroup (n=4475) versus “all other participants” (n=6975
individuals not receiving a regimen containing an RAS blocker
plus either a diuretic or CCB on enrollment). There were 56
participants not taking any BP medication on enrollment into
the trial who were not included in our current study, giving us
a total sample size of 11 450. There were some small, but
statistically significant, differences in characteristics between
subgroups. However, this is not relevant in regard to the
objectives of this study, which aimed to assess the efficacy of
benazepril+amlodipine in both groups, irrespective of poten-
tial differences in characteristics.
The following results are from the individual subgroup
analyses. In the primary subgroup, there were 206 of 2193
(9.4%) composite study events among individuals random-
ized to benazepril+amlodipine versus 281 of 2282 (12.3%)
among those allocated to benazepril+hydrochlorothiazide
(adjusted HR, 0.74; 95% CI, 0.62–0.89; P=0.0015) (Fig-
ure 1). In all other participant subgroups, those assigned to
benazepril+amlodipine (adjusted HR, 0.84; 95% CI, 0.72–
0.98; P=0.024) also benefited (Figure 2). Confining the
analyses to a “limited primary subgroup,” including individ-
uals previously taking a 2-drug regimen consisting of only an
RAS blocker plus either a thiazide-like diuretic or CCB (ie, no
additional antihypertensive agent of any class in their
regimen), yielded similar results. In this limited primary
subgroup (n=2266), there were 97 of 1140 (8.5%) composite
No. at risk
B+A 2282 2120 1982 1198
B+H 2193 2068 1958 1184
Figure 1. Composite trial outcomes in the primary subgroup. Survival curves among individuals in the primary subgroup: previously
taking an antihypertensive regimen consisting of any renin-angiotensin system blocker (angiotensin-converting enzyme inhibitor or
angiotensin receptor blocker) plus (either a diuretic or calcium channel blocker) as part of their antihypertensive regimen who were
randomized to benazepril (B)+amlodipine (A) (solid line) vs B+hydrochlorothiazide (H) (broken line). P value is for hazard ratio by log-rank
test.
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study events among individuals randomized to benazepril+
amlodipine versus 117 of 1126 (10.4%) among those
allocated to benazepril+hydrochlorothiazide (adjusted HR,
0.80; 95% CI, 0.61–1.04; P=0.099). Given the similar HR to
that of the primary subgroup, the borderline nonsignificant P
value is likely attributable to a smaller sample size. All other
participants not in the limited primary subgroup (n=9184)
also benefited from assignment to benazepril+amlodipine
(HR, 0.80; 95% CI, 0.70–0.91; P=0.0006). Controlling for
achieved BP levels at 6 months into the trial did not
substantively alter the results for any of the previously
described subgroups.
Although not always statistically significant, the HRs also
favored randomization to benazepril+amlodipine for most
other subgroups in secondary analyses on the basis of
preenrollment or background drug regimens, including those
taking lipid-lowering medications or with a systolic BP of
<140 mm Hg on study enrollment (Figure 3). With 1
exception (ACEI+CCB), the rates of the main composite
end points were similar across subgroups within the same
treatment limb, ranging from 8.9% to 9.8% for
benazepril+amlodipine and from 9.9% to 16.0% for
benazepril+hydrochlorothiazide. Composite end point rates
were higher in the benazepril+hydrochlorothiazide compared
with the benazepril+amlodipine treatment limb in all
subgroups (Table 2).
The following results are for the model involving the
entire cohort of patients that included an interaction term to
No. at risk
B+A 3452 3215 3015 1741
B+H 3523 3310 3131 1848
Figure 2. Composite trial outcomes among all other participants not in the primary subgroup. Survival curves among all other individuals not
in the primary subgroup who were randomized to benazepril (B)+amlodipine (A) (solid line) vs B+hydrochlorothiazide (H) (broken line). P value is
for hazard ratio by log-rank test.
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test for effect modification on the HRs by subgroups (prior
treatments). Other than for the ACEI+CCB subgroup, there
was no evidence of effect modification (nonsignificant
interaction terms) on the main composite end point for
any other subgroup evaluated (Table 3). To explore for
reasons underlying the greater benefit in the ACEI+CCB
subgroup, we evaluated for differences in characteristics
among these participants (Table 4). Although some clinical
variables were statistically different, adding these to the
model did not eliminate the significance of the interaction
term (P=0.006). Controlling for achieved BP levels at 6
months into the trial also did not substantively alter these
findings.
Discussion
The main finding of this post hoc observational analysis of the
ACCOMPLISH trial is that patients who were previously
receiving a combination antihypertensive regimen similar to
either treatment limb used in the study (ie, RAS blocker+di-
uretic or CCB) derived cardiovascular benefit from allocation
to benazepril+amlodipine. The risk reduction for the
Figure 3. Composite trial outcomes among additional secondary subgroups. Forest plot representing the adjusted hazard ratios95%
confidence intervals by Cox proportional hazard model in favor of benazepril (B)+amlodipine (A) therapy by secondary subgroups. In each
antihypertensive medication subgroup, participants were taking the specific medication(s) listed without overlap between unique subgroups.
Patients could not be included in >1 subgroup. For example, patients in the calcium channel blocker (CCB) alone, ACEI (angiotensin-converting
enzyme inhibitor) alone, ACEI+CCB, and ACEI+diuretic subgroups were all different individuals. The exception is that there were overlaps in
patients between subgroups containing the term “or” in the definition. For example, patients could be in both the ACEI+diuretic group and the
ACEI or angiotensin receptor blocker [ARB]+diuretic subgroup. Patients using other antihypertensive agents not listed in the figure (eg, b or a
blockers) were not excluded from these subgroups. Other subgroups listed include background lipid-lowering therapy and systolic blood
pressure (SBP) control status on trial randomization. CI indicates confidence interval; H, hydrochlorothiazide; HMG-CoA, 3-hydroxy-3-
methylglutaryl coenzyme-A reductase inhibitor (statin); and mod, modifying.
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composite end point was similar in this primary subgroup
(26%) and among all other participants (15%) and the overall
trial cohort (20%).6 This suggests that cardiovascular protec-
tion can be improved not only by switching patients taking an
RAS blocker+diuretic to combination therapy using
benazepril+amlodipine, but also by continuing the latter
regimen among individuals already receiving it. These findings
are relevant to present-day clinical practice because both
regimens remain advocated as viable strategies by recent
guidelines2–4 for patients requiring combination therapy to
achieve BP control.6–10
No subgroup appeared to be harmed (all HRs, <1.0) by
allocation to benazepril+amlodipine, including those previ-
ously taking any antihypertensive regimen other than those
used in the primary subgroup, those taking background
cholesterol-lowering agents, and patients with systolic BP
already controlled to target goal (Figure 3). It is possible that
some of the HRs may not have reached traditional levels of
significance principally because of reduced statistical power,
given the smaller subgroup sample sizes. Nonetheless, in
each scenario, the risk reductions trended in favor of
benazepril+amlodipine. There was also no evidence of
significant effect modification of any subgroup on the main
composite outcome, except for greater benefit among those
previously taking an ACEI+CCB (Tables 2 and 3). The reasons
for this latter observation are not clear; however, it further
supports maintaining this regimen among those already
receiving it.
Clinical Implications
Taken together with previous ACCOMPLISH trial results,6 our
current findings add support to the contention that high-risk
hypertensive patients will likely benefit, or at the least will not
be harmed, by converting their BP-lowering regimen to
combination therapy using benazepril+amlodipine. This
applies to diabetic patients, patients with coronary heart
disease, and those at risk for adverse renal outcomes.6–10 In
the present analysis, even individuals with controlled hyper-
tension (ie, systolic BP of <140 mm Hg) or taking only a
single antihypertensive agent benefitted (or trended towards
benefit).
Greater BP-lowering efficacy of benazepril+amlodipine is
unlikely to explain its superiority because 24-hour ambula-
tory levels did not differ between treatment limbs in a
subgroup analysis (n=573) of participants in the ACCOM-
PLISH trial.10 We have previously reviewed several
Table 2. Composite Primary Event Rates in the Treatment
Limbs for Each Subgroup
Study Subgroup
Benazepril+
Amlodipine
Limb
Events (%)
Benazepril+
Hydrochlorothiazide
Limb
Events (%)
ACEI+CCB (n=1375) 60 (8.88) 112 (16.0)
ACEI+diuretic (n=1419) 64 (9.40) 79 (10.7)
ACEI or ARB+diuretic (n=2745) 124 (9.25) 151 (10.75)
ARB+diuretic (n=1326) 60 (9.19) 72 (10.79)
ACEI alone (n=2562) 127 (9.67) 136 (10.9)
(ACEI or ARB alone) or
([ACE or ARB]+diuretic)
(n=6336)
295 (9.37) 340 (10.65)
Not ACEI or ARB+CCB
or diuretic (n=6975)
323 (9.16) 372 (10.77)
CCB alone (n=717) 35 (9.49) 40 (11.5)
ACEI or ARB alone (n=3591) 171 (9.46) 189 (10.58)
ARB alone (n=1032) 44 (8.91) 53 (9.85)
Statin only or with other
lipid-lowering drug (n=7635)
365 (9.75) 462 (11.87)
Baseline systolic
BP ≥140 mm Hg (n=6977)
327 (9.44) 426 (12.13)
Baseline systolic
BP <140 mm Hg (n=4480)
202 (8.96) 227 (10.2)
ACE indicates angiotensin-converting enzyme; ACEI, ACE inhibitor; ARB, angiotensin
receptor blocker; BP, blood pressure; and CCB, calcium channel blocker.
Table 3. Significance of the Interaction Terms for Effect
Modification for Each Subgroup on the HR Between Study
Treatment Limbs
Study Subgroup
P Value for
Interaction
Term
ACEI+CCB (n=1375) 0.005
ACEI+diuretic (n=1419) 0.844
ACEI or ARB+diuretic (n=2745) 0.688
ARB+diuretic (n=1326) 0.739
ACEI alone (n=2562) 0.431
ACEI or ARB+CCB or diuretic (n=4475) 0.307
Not ACEI or ARB+CCB or diuretic (n=6975) 0.307
CCB alone (n=717) 0.752
ACEI or ARB alone (n=3591) 0.383
ARB alone (n=1032) 0.797
Statin only or with other lipid-lowering drug (n=7635) 0.769
Baseline systolic BP ≥140 mm Hg (n=6977) 0.551
Baseline systolic BP <140 mm Hg (n=4480) 0.551
Model adjusted for baseline age, smoking status, history of myocardial infarction,
coronary revascularization, hospitalization for unstable angina, systolic and diastolic BP,
and left ventricular hypertrophy. ACEI indicates angiotensin-converting enzyme inhibitor;
ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker;
and HR, hazard ratio.
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hypotheses, including therapeutic reasons (eg, reduced drug-
related adverse effects and better compliance) and biological
mechanisms (eg, greater central aortic BP lowering),
plausibly responsible for the greater cardiovascular risk
reduction derived from initial combination therapy using
benazepril+amlodipine as opposed to other regimens.5
Nevertheless, the underlying explanation(s) for these current
findings and the main ACCOMPLISH trial results must remain
speculative at the present time.
The evidence from several trials11,12 and observational
analyses13 supports that starting a 2-drug regimen (ie, “initial”
combination therapy) rather than a single antihypertensive
agent cannot only achieve more rapid and superior BP
control,4 but may also lead to better cardiovascular out-
comes.14 These prior studies demonstrated the benefits of
initial combination therapy in a variety of regimens. Given the
superiority of benazepril+amlodipine versus benazepril+hy-
drochlorothiazide (even among patients taking at least 2 BP
medications6), we posit that initial combination therapy
specifically with RAS blockade plus CCB (when clinically
appropriate and not contraindicated) may be an even more
effective management strategy for the prevention of cardio-
vascular events than estimated by prior combination therapy
studies.11–14
Strengths and Limitations
We are aware of only 1 prior analysis from a major
hypertension trial (VALUE [Valsartan Antihypertensive Long-
Term Use Evaluation]) in which the impact on study outcomes
was evaluated in relation to prior BP-lowering treatment
regimens.15 As with the ACCOMPLISH trial, most study
patients (92%) had been receiving antihypertensive therapy
before entering the VALUE trial. In accordance with our
findings, the study end points were not differentially affected
Table 4. Characteristics of the Study Participants in the
ACEI+CCB Subgroup Versus All Other Participants
Subject Characteristics ACEI+CCB
All Other
Participants P Value
Subjects, n (%) 1375 (12.0) 10 075 (88.0)
Sex, n (%) 0.121
Male 860 (62.6) 6082 (60.4)
Female 515 (37.5) 3993 (39.6)
Age, meanSD, y 68.47.1 68.46.8 0.996
≥65 y, n (%) 897 (65.2) 6703 (66.5) 0.341
≥70 y, n (%) 563 (41.0) 4113 (40.8) 0.931
Race or ethnic group, n (%) 0.0002
Black 242 (17.6) 1130 (11.2) <0.0001
White 1074 (78.1) 8527 (84.6) <0.0001
Hispanic 85 (6.2) 537 (5.3) 0.191
Other 54 (3.9) 374 (3.7) 0.693
Region, n (%) <0.0001
United States 1138 (82.8) 6959 (69.1)
Nordic countries 237 (17.2) 3116 (30.9)
Anthropometrics, meanSD
Weight, kg 89.019.0 88.518.9 0.396
Waist circumference, cm 104.016.2 103.815.2 0.714
Body mass index,
kg/m2
31.16.2 30.96.2 0.354
Medications, n (%)
Lipid-lowering agents 939 (68.9) 6756 (67.8) 0.393
b Blockers 584 (42.9) 4797 (48.1) 0.0003
Antiplatelet agents 876 (64.3) 6292 (63.1) 0.396
Hemodynamics, meanSD
Systolic BP, mm Hg 144.717.9 145.518.3 0.131
Diastolic BP, mm Hg 79.010.6 80.210.8 0.0002
Heart rate, beats/min 70.810.7 70.311.0 0.126
Laboratory values, meanSD
Creatinine, mg/dL 0.970.28 0.990.27 0.055
Glucose, mg/dL 128.448.0 127.346.1 0.431
Potassium, mmol/dL 4.30.4 4.30.4 0.535
Total cholesterol, mg/dL 183.538.2 184.539.8 0.418
HDL-C, mg/dL 49.614.2 49.414.0 0.788
Risk factors, n (%)
Myocardial infarction 294 (21.4) 2409 (23.9) 0.038
Stroke 188 (13.7) 1305 (13.0) 0.457
Hospitalization for
United States
166 (12.1) 1157 (11.5) 0.522
Diabetes mellitus 851 (61.9) 6053 (60.1) 0.198
Renal disease 118 (8.6) 584 (5.8) <0.0001
Continued
Table 4. Continued
Subject Characteristics ACEI+CCB
All Other
Participants P Value
Coronary revascularization 512 (37.2) 3595 (35.7) 0.260
CABG 315 (22.9) 2124 (21.1) 0.121
PCI 275 (20.0) 1898 (18.8) 0.303
Other, n (%)
LVH 176 (13.2) 1351 (13.7) 0.586
Current smoking 157 (11.4) 1138 (11.3) 0.893
Dyslipidemia 1060 (77.1) 7473 (74.2) 0.02
Atrial fibrillation 90 (6.6) 686 (6.8) 0.715
ACEI indicates angiotensin-converting enzyme inhibitor; BP, blood pressure; CABG,
coronary artery bypass grafting; CCB, calcium channel blocker; HDL-C, high-density
lipoprotein cholesterol; LVH, left ventricular hypertrophy; and PCI, percutaneous
coronary intervention.
DOI: 10.1161/JAHA.117.006940 Journal of the American Heart Association 8
Prior Medications and Antihypertensive Therapy Brook et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
by prior medications. This is a particularly relevant issue for
contemporary clinical practice because most patients among
modern trials had been already undergoing treatment with
medications.1
We acknowledge that our results derive from post hoc
observational analyses and, as such, must be considered
hypothesis generating. Nevertheless, the consistency of
responses favoring benazepril+amlodipine among all sub-
groups supports the overall veracity of our overarching
contention. In addition, our findings only directly apply to
high-risk individuals given the characteristics of the patients in
ACCOMPLISH.6 Whether the results can be extrapolated to
other and lower-risk patients is unknown; however, recent
evidence supports that medical treatment is likely beneficial,
even for low-risk patients with mild hypertension.1 Positive
findings in our studywere observed in patients previously taking
several single BP-lowering medications and those with a
systolic/diastolic BP of <140/90 mm Hg, supporting the
hypothesis that even individuals with milder forms of high BP
may benefit from benazepril+amlodipine. The average on-
treatment BP in the ACCOMPLISH trial was <140/90 mm Hg.
Thus, any speculations of the merits of initiating combination
therapywith benazepril+amlodipine implicitly presume that this
regimen is capable of keeping BP controlled (alone or with
additional agents as needed). This is particularly important
given the recent results of the SPRINT (Systolic Blood Pressure
Intervention Trial), which also supports a lower systolic BP
target (120 mm Hg) than previously espoused.16 Patients were
allocated to a subgroup on the basis of the medications they
were taking right at study enrollment. The duration they had
been treated with these agents, prior medication use in the
years beforehand, and their adherence to this regimen remain
unknown. However, because most subgroups derived similar
relative benefits from benazepril+amlodipine, it is not likely that
any unaccounted for changing of priormedications between the
various regimens in themonths to years before entering the trial
would have differentially affected the treatment effects of the
combination therapy regimens used in the ACCOMPLISH trial in
amanner that explains our current findings. Finally, wewere not
able to explain the significantly greater benefit of
benazepril+amlodipine in the ACEI+CCB subgroup (Table 3).
It remains possible that unaccounted for factors (ie, not listed in
Table 4) could have led to a propensity to receive ACEI+CCB
combination and, thus, explains the greater benefit in this 1
subgroup.
Conclusions
High-risk hypertensive patients achieved a greater cardiovas-
cular risk reduction by allocation to benazepril+amlodipine
compared with benazepril+hydrochlorothiazide, largely
regardless of their prior medication treatment regimens,
baseline BP control status, and background lipid-lowering
therapies. Our findings add further support that most
hypertensive patients should strongly consider combination
RAS blocker/CCB as first-line therapy.
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